Valuation: Lantheus Holdings, Inc.

Market Cap 6.51B 5.78B 5.36B 4.88B 9.21B 618B 9.35B 64.45B 25.27B 322B 24.42B 23.9B 1,027B P/E 2026 *
21.1x
P/E 2027 * 17.9x
Enterprise Value 6.29B 5.59B 5.18B 4.71B 8.9B 597B 9.04B 62.28B 24.42B 311B 23.6B 23.1B 993B EV / Sales 2026 *
4.27x
EV / Sales 2027 * 3.57x
Free-Float
88.47%
Yield 2026 *
-
Yield 2027 * -
1 day+0.17%
1 week-0.29%
Current month+0.29%
1 month-0.46%
3 months-4.39%
6 months+18.88%
Current year+49.99%
1 week 99.6
Extreme 99.595
100.28
1 month 99.31
Extreme 99.31
100.96
Current year 63.37
Extreme 63.37
111.86
1 year 50.16
Extreme 50.155
111.86
3 years 47.25
Extreme 47.25
126.89
5 years 22.52
Extreme 22.515
126.89
10 years 7.95
Extreme 7.95
126.89
Manager TitleAgeSince
Chief Executive Officer 66 2025-12-31
Director of Finance/CFO 60 2018-09-20
Chief Tech/Sci/R&D Officer 64 2025-07-31
Director TitleAgeSince
Director/Board Member 80 2012-04-30
Chairman 66 2024-02-29
Director/Board Member 61 2016-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Tax

Chief Financial Officer

-721 0.0011%
8/17/26 Tax

Controller/Auditor

-463 0.0007%
8/17/26 Tax

Chief Technology Officer

-2,536 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+0.17%-0.29%+76.36%+44.23% 6.51B
-0.96%+2.05%-19.77%+8.87% 181B
-2.03%+1.04%-3.16%+28.39% 116B
+0.95%+5.09%-22.09%+10.64% 113B
-1.36%+3.78%-51.48%-6.07% 79.83B
-0.98%+3.94%+3.20%+77.93% 65.06B
-0.27%+2.10%+15.54%+66.81% 54.35B
-0.68%+0.73%-0.38%-26.10% 52.23B
-0.77%+6.08%-13.62%+30.56% 44.15B
-0.14%-0.20%+25.31%-0.34% 32.47B
Average -0.61%+4.62%+0.99%+23.49% 74.51B
Weighted average by Cap. -0.76%+5.45%-11.83%+19.58%

Financials

2026 *2027 *
Net sales 1.47B 1.31B 1.21B 1.1B 2.08B 140B 2.12B 14.6B 5.72B 73B 5.53B 5.41B 233B 1.65B 1.47B 1.36B 1.24B 2.34B 157B 2.38B 16.38B 6.42B 81.9B 6.21B 6.07B 261B
Net income 320M 284M 263M 240M 452M 30.33B 459M 3.16B 1.24B 15.83B 1.2B 1.17B 50.45B 392M 349M 323M 294M 555M 37.23B 564M 3.88B 1.52B 19.43B 1.47B 1.44B 61.94B
Net Debt -219M -194M -180M -164M -309M -20.75B -314M -2.16B -849M -10.83B -820M -803M -34.51B -598M -531M -492M -448M -845M -56.73B -859M -5.92B -2.32B -29.6B -2.24B -2.2B -94.37B
Projected Income Statement - Annual - Lantheus Holdings, Inc.
Logo Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
Employees
1,193
Date Price Change Volume
26-10-19 US$99.82 +0.12% 381,860
26-10-16 US$99.70 -0.29% 1,711,646
26-10-15 US$99.99 -0.01% 866,503
26-10-14 US$100.00 -0.02% 936,668
26-10-13 US$100.02 -0.09% 1,536,472
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Lantheus Holdings, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
99.70USD
Average target price
106.99USD
Spread / Average Target
+7.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lantheus Holdings, Inc.
  1. Stock Market
  2. Stocks
  3. LNTH Stock